- Home
- CABA vs BMEA Comparison
CABA vs BMEA Comparison
Compare CABA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- BMEA
- Stock Information
- Founded
- CABA 2017
- BMEA 2017
- Country
- CABA United States
- BMEA United States
- Employees
- CABA N/A
- BMEA N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- CABA Health Care
- BMEA Health Care
- Exchange
- CABA Nasdaq
- BMEA Nasdaq
- Market Cap
- CABA 118.8M
- BMEA 125.4M
- IPO Year
- CABA 2019
- BMEA 2021
- Fundamental
- Price
- CABA $1.19
- BMEA $1.95
- Analyst Decision
- CABA Strong Buy
- BMEA Buy
- Analyst Count
- CABA 10
- BMEA 12
- Target Price
- CABA $24.80
- BMEA $28.45
- AVG Volume (30 Days)
- CABA 896.7K
- BMEA 689.2K
- Earning Date
- CABA 05-14-2025
- BMEA 05-01-2025
- Dividend Yield
- CABA N/A
- BMEA N/A
- EPS Growth
- CABA N/A
- BMEA N/A
- EPS
- CABA N/A
- BMEA N/A
- Revenue
- CABA N/A
- BMEA N/A
- Revenue This Year
- CABA N/A
- BMEA N/A
- Revenue Next Year
- CABA N/A
- BMEA N/A
- P/E Ratio
- CABA N/A
- BMEA N/A
- Revenue Growth
- CABA N/A
- BMEA N/A
- 52 Week Low
- CABA $1.15
- BMEA $1.87
- 52 Week High
- CABA $19.04
- BMEA $14.43
- Technical
- Relative Strength Index (RSI)
- CABA 27.22
- BMEA 29.50
- Support Level
- CABA $1.16
- BMEA $1.87
- Resistance Level
- CABA $1.85
- BMEA $2.29
- Average True Range (ATR)
- CABA 0.14
- BMEA 0.24
- MACD
- CABA -0.04
- BMEA -0.03
- Stochastic Oscillator
- CABA 6.21
- BMEA 6.63
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.